source
- Biohaven secures up to $795 million partnership with SK Biopharma for global epilepsy drug rightsBiohaven announced a commercial partnership for its late-stage epilepsy program. South Korea-based SK Biopharma has agreed to pay up to $795 million for worldwide rights to the company's Kv7 ion ch…
- Hansoh says China’s biopharma is shifting from follower to frontrunner, now behind 30% of investigational drugsHansoh Pharmaceutical used its first‑half earnings release to claim that China’s innovative biopharma sector is moving from a follower role to a frontrunner position. The company highlighted that…